• Applied Workflows with YC-1 in Hypoxia and Cancer Research

  2026-05-02

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol empowers researchers to dissect hypoxic signaling and tumor angiogenesis with dual-action inhibition and activation properties. Learn how APExBIO’s high-purity YC-1 streamlines robust in vitro assays and maximizes reproducibility in advanced cancer biology applications.

• Sulfo-Cy5 Carboxylic Acid: Fluorescent Dye for Life Sciences

  2026-05-02

  Sulfo-Cy5 carboxylic acid delivers unmatched hydrophilicity and minimal quenching, optimizing protein and peptide labeling for high-sensitivity fluorescence imaging. This guide translates current research and real-world protocols into actionable workflows, ensuring reproducible results across neuroscience, immunology, and advanced vaccine development.

• E-64d (SKU A1903): Reliable Cysteine Protease Inhibition in

  2026-05-01

  Explore how E-64d (SKU A1903), a membrane-permeable cysteine protease inhibitor, addresses core challenges in apoptosis, neuroprotection, and platelet assays. This article provides scenario-driven guidance for optimizing protocols, interpreting data, and selecting high-quality reagents—grounded in evidence and best practices—helping researchers achieve reproducible, insightful results.

• Firefly Luciferase mRNA (ARCA, 5-moUTP): Applied Workflows &

  2026-04-30

  Firefly Luciferase mRNA (ARCA, 5-moUTP) delivers unmatched bioluminescence, immune evasion, and translational efficiency for gene expression, cell viability, and in vivo imaging assays. This guide translates cutting-edge research and product engineering into actionable protocols and troubleshooting strategies for robust, reproducible results.

• Sulfamonomethoxine Toxicity in Aquatic Species: Ecosystem Ri

  2026-04-30

  This article analyzes the acute and chronic toxicity of sulfamonomethoxine (SMM) across five aquatic species, revealing marked sensitivity differences—especially among microalgae and cladocerans. The study's systematic assay design and its implications for environmental risk assessment are discussed, with practical connections to optimizing buffer systems in aquatic toxicology.

• RAS/PI3K Mutations Sensitize Ovarian Cancer to PARP/NAMPT In

  2026-04-29

  This study reveals that epithelial ovarian cancer cells with RAS/PI3K pathway mutations exhibit increased sensitivity to combined PARP and NAMPT inhibition. The findings offer a mechanistic rationale for targeted combination therapies, highlighting how metabolic vulnerabilities in specific genetic backgrounds can be leveraged to overcome resistance in ovarian cancer maintenance treatment.

• Anti-ROR1 Antibody (Zilovertamab): Mechanistic Depth for Nex

  2026-04-29

  Explore the advanced mechanistic underpinnings and experimental protocols of Anti-ROR1 Antibody (Zilovertamab) in cancer research. This cornerstone article delivers unique insight into Wnt5a-induced ROR1 signaling inhibition and guides the selection of optimal assay parameters.

• Technical Guide: HyperScribe™ T7 High Yield Cy3 RNA Labeling

  2026-04-28

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus addresses the need for efficient, high-yield preparation of randomly Cy3-labeled RNA probes for sensitive fluorescent detection. It is best used for in situ hybridization and Northern blot probe synthesis, but should not be used for diagnostic or therapeutic applications. This kit ensures robust incorporation of Cy3-UTP and is designed strictly for research workflows.

• Alda 1: Advanced ALDH2 Activator for Cardiac Ischemia Resear

  2026-04-28

  Alda 1 enables robust and reproducible activation of ALDH2, including the ALDH2*2 variant, for cutting-edge cardiac ischemia and dermatitis research. Its unique mechanism and validated workflows offer translational scientists a powerful tool for probing aldehyde detoxification and cardioprotection.

• High-Throughput BBB Permeability Prediction Using LLC-PK1-MD

  2026-04-27

  This study establishes a high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells with lysosomal trapping correction to predict CNS drug permeability. The model demonstrates strong correlation with in vivo brain distribution, providing a robust tool for early-stage CNS drug development and screening.

• Phosbind Biotin: Sequence-Independent Detection of Phosphory

  2026-04-27

  Phos binding reagent (Phosbind) Biotin enables sensitive, antibody-independent detection of phosphorylated proteins in Western Blots. Utilizing dinuclear metal complex phosphate binding, it provides robust signal transduction pathway analysis and overcomes sequence context limitations. This product supports reproducible protein phosphorylation analysis in both fundamental and applied research.

• RNF166 Destabilizes Poly-ADP-Ribosylated Angiomotins in CRC

  2026-04-26

  This study identifies RNF166 as a key E3 ubiquitin ligase that promotes colorectal cancer by targeting poly-ADP-ribosylated angiomotins for degradation, leading to YAP activation. These findings reveal a new regulatory axis in the Hippo pathway and provide a potential therapeutic target in colorectal cancer.

• H-89: Advancing cAMP-Dependent Protein Kinase Inhibitor Assa

  2026-04-25

  Leverage H-89 for precision dissection of cAMP signaling in metabolic and osteogenic pathways. This guide translates mechanistic breakthroughs into actionable protocols and troubleshooting tips, optimizing your signaling research for reproducibility and clarity.

• Optimized Sulfonamides with Reduced CYP2C9 Inhibition for TB

  2026-04-24

  Chen et al. report the systematic optimization of sulfaphenazole-based sulfonamides to enhance antimycobacterial efficacy while minimizing CYP 2C9 inhibition. This work advances safer tuberculosis drug design by reducing drug-drug interaction risk without compromising activity.

• MLN2238: Mechanistic Insights and CREB Axis Implications in

  2026-04-24

  Explore the advanced mechanisms of MLN2238, a potent proteasome β5 subunit inhibitor, with new insights into CREB signaling and oxidative stress. This article uniquely integrates molecular actions with translational assay decisions for multiple myeloma and lymphoma research.

458 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page